Recently added articles from Biotech Business:

OXIGENE BEGINS PHASE II NSCLC TRIAL OF ZYBRESTAT WITH CHEMOTHERAPY.

May 01, 2008 ... OXiGENE, Inc., Waltham, Mass., a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced that the company has begun dosing patients in a randomized, double-blinded, controlled Phase II study of its potential first-in-class vascular ...

THE GI COMPANY TO PRESENT PHASE II ORAL MUCOSITIS DATA AT ASCO.

May 01, 2008 ... The GI Company, Inc., Framingham, Mass., a privately held developer of gastrointestinal therapeutics, has announced that an abstract detailing results from a Phase II clinical trial (2006 - ITF - 009) has been accepted for oral presentation at the 2008 Annual Meeting of the American ...

WEILL CORNELL INDENTIFIES NEW FORM OF INHERITED CANCER RISK.

May 01, 2008 ... Like the subtext of a novel, the human genome sequence harbors more information than appears just in its "letters" of A, C, T and G. Since DNA is a data-packed molecule passed from generation to generation, comparing genome sequences among individuals also holds clues to ancestry. ...

IMMUNEREGEN/DELSITE COLLABORATE ON NEW FLU TREATMENT.

May 01, 2008 ... ImmuneRegen(r) BioSciences, Inc., Scottsdale, Ariz., a wholly owned biotechnology product development and licensing subsidiary of IR BioSciences Holdings, Inc. (OTCBB:IRBO), has commenced a collaboration with DelSite Biotechnologies, Inc., a wholly owned subsidiary of Carrington ...